Danon Disease Natural History Study
← catalyst calendarNCT06214507 · readout ≤ 1,230 d
Sponsored by Rocket Pharmaceuticals Inc. (industry) · RCKT — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
60estimated
Sites
15
Countries
Germany, Israel, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-20 | actual | When the study began enrolling |
| Primary completion | Dec 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Danon Disease
Intervention
- Other: No intervention
Primary outcome
what the primary-completion date above is the date OFLeft Ventricular Mass Index (LVMI) by echocardiogram
measured Month 12, 24, 36
Permalink · RCKT's whole pipeline · Catalyst calendar · Every registered study · What changed